JP2017525712A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525712A5
JP2017525712A5 JP2017510539A JP2017510539A JP2017525712A5 JP 2017525712 A5 JP2017525712 A5 JP 2017525712A5 JP 2017510539 A JP2017510539 A JP 2017510539A JP 2017510539 A JP2017510539 A JP 2017510539A JP 2017525712 A5 JP2017525712 A5 JP 2017525712A5
Authority
JP
Japan
Prior art keywords
tablet
contained
range
tablet according
azepino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017510539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525712A (ja
JP6574477B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/045522 external-priority patent/WO2016028689A1/en
Publication of JP2017525712A publication Critical patent/JP2017525712A/ja
Publication of JP2017525712A5 publication Critical patent/JP2017525712A5/ja
Application granted granted Critical
Publication of JP6574477B2 publication Critical patent/JP6574477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017510539A 2014-08-22 2015-08-17 ルカパリブの高投与力価錠剤 Active JP6574477B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149084A Division JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤

Publications (3)

Publication Number Publication Date
JP2017525712A JP2017525712A (ja) 2017-09-07
JP2017525712A5 true JP2017525712A5 (2) 2018-09-27
JP6574477B2 JP6574477B2 (ja) 2019-09-11

Family

ID=55347324

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017510539A Active JP6574477B2 (ja) 2014-08-22 2015-08-17 ルカパリブの高投与力価錠剤
JP2019149084A Active JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤
JP2020191356A Active JP7127101B2 (ja) 2014-08-22 2020-11-18 ルカパリブの高投与力価錠剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019149084A Active JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤
JP2020191356A Active JP7127101B2 (ja) 2014-08-22 2020-11-18 ルカパリブの高投与力価錠剤

Country Status (23)

Country Link
US (3) US9987285B2 (2)
EP (1) EP3182975B1 (2)
JP (3) JP6574477B2 (2)
KR (2) KR102803917B1 (2)
CN (2) CN106794185A (2)
AU (2) AU2015305696B2 (2)
BR (1) BR112017000865A2 (2)
CA (1) CA2955495C (2)
DK (1) DK3182975T3 (2)
ES (1) ES3048688T3 (2)
FI (1) FI3182975T3 (2)
HR (1) HRP20251484T1 (2)
IL (1) IL249946B (2)
LT (1) LT3182975T (2)
MX (1) MX367260B (2)
NZ (1) NZ728392A (2)
PL (1) PL3182975T3 (2)
PT (1) PT3182975T (2)
RS (1) RS67356B1 (2)
RU (1) RU2705156C2 (2)
SG (1) SG11201700265VA (2)
SI (1) SI3182975T1 (2)
WO (1) WO2016028689A1 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
WO2018140377A1 (en) 2017-01-24 2018-08-02 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
TWI843707B (zh) * 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼(niraparib)調配物
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
US20230234938A1 (en) 2020-04-28 2023-07-27 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
CA3214298A1 (en) 2021-04-08 2022-10-13 Swaroop Kumar Venkata Satya VAKKALANKA Inhibitors of poly(adp-ribose) polymerase
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック,インコーポレイテッド ルカパリブ粒子およびその使用
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495541B1 (en) 1999-01-11 2002-12-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(ADP-ribose) polymerases
CA2520997A1 (en) 2003-03-31 2004-10-14 Stacie Sara Canan-Koch Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
US7531530B2 (en) 2003-07-25 2009-05-12 Cancer Research Technology Limited Therapeutic compounds
MX2007003314A (es) 2004-09-22 2007-08-06 Pfizer Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
ATE551345T1 (de) 2004-09-22 2012-04-15 Pfizer Polymorphe formen des phosphatsalzes von 8-fluor- 2-ä4-ä(methylamino)methylüphenylü-1,3,4,5- tetrahydro-6h-azepinoä5,4,3-cdüindol-6-on
PT1794163E (pt) 2004-09-22 2010-03-01 Pfizer Método para a preparação de inibidores de poli(adpribose)- polimerases
CA2720744A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
CN108478577A (zh) * 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib

Similar Documents

Publication Publication Date Title
JP2017525712A5 (2)
RU2017109139A (ru) Таблетки, содержащие большую дозу рукапариба
TWI583384B (zh) 包含4-胺基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸鹽單水合物之醫藥組合物
JP7023945B2 (ja) レナリドミドの経口用錠剤組成物
JP6245677B2 (ja) 口腔内崩壊錠
JP2011098964A5 (2)
ES2311442T1 (es) Dosis en forma oral.
CN104661649A (zh) 包含替格瑞洛的固态口服医药制剂
WO2015029074A2 (en) Compositions of eltrombopag
JP2015521191A5 (2)
CN101478966B (zh) 压缩制剂
CN105073100A (zh) 坦索罗辛或其盐的药物组合物
CA2764172A1 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
JP2005538097A (ja) Hmg−coaレダクターゼインヒビターを含む組成物
CN101312714A (zh) 替米沙坦的药用组合物
KR20180083239A (ko) 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물
CA2833115C (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
WO2014058047A1 (ja) カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤の製造方法
WO2011080706A1 (en) Enhanced solubility of ziprasidone
KR20100083047A (ko) 생체이용률이 향상된 발사르탄을 포함하는 약제학적 조성물
WO2016012898A1 (en) Oral pharmaceutical composition of lurasidone
JP2016539109A (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法
JP5241511B2 (ja) 溶出性の改善された医薬組成物
JP2007512287A5 (2)